Antigen presentation function, 244–245

Aplastic anemia, 21

Asian American donors, 50, 87, 248

standards for, 98

Aspergillis, 59

Aspilt@, 251

Australian donors, standards for, 98

Autoimmune diseases, treating, 57

Autologous transplantation, 43–44, 297

indications for stem cell support, 39–40

Available units, across all banks, 166

B

Banks. See Cord blood banks

Bar coding, 84, 177

Beta thalessemia, clinical use of cord blood in treating, 62

Biological characteristics, of umbilical cord blood, 33–38

“Biological life insurance,” 78

Biological Response Modifiers Advisory Committee (BRMAC), 93–94

Bone marrow (BM), 45, 209–217

failures treatable by transplantation of cord blood, 63

Bone Marrow Donors Worldwide (BMDW), 122–123, 258

Bone marrow transplantation (BMT), 47, 172

aftermath of, 209–210

Brain injury, 67–68

non-stroke-related brain damage, 67–68

stroke, 67

umbilical cord blood in, 67–68

C

California donors, 87

Canadian donors, standards for, 98

Cardiac repair, umbilical cord blood in, 65–66

Cardiac stem cell precursors, 66

Cardiomyocytes, 212–213

Carolinas Cord Blood Bank, 48, 80

Caucasian donors, 37, 50, 87, 236, 238, 248

Caucasian recipients, 235

CD34* cell counts, 40, 50, 58, 61, 67, 82–83, 93–94, 171

Cell viability, 171

transport of cord blood and, 83–84

Cellular Therapies Standards Program Unit, 96

Center for International Blood and Marrow Transplant Research (CIBMTR), 34–35

Centers for Disease Control (CDC), Health Information for International Travel, 191

Central nervous system disease, umbilical cord blood in, 66

Chimerism, 58, 212, 297

double, 59

hematological, 68

Circulating cells, contribution to nonhematopoietic tissues in clinical specimens, 212

Citrate dextrose solution, formula A (ACD-A), an anticoagulant, 205

Citrate-phosphate-dextrose (CPD), an anticoagulant, 81, 205

Clinical Laboratory Improvement Amendments (CLIA), 248

Clinical testing and quality control, 248–249

Clinical use of cord blood in treating inherited diseases, examples of effective, 62

Colitis, ulcerative, 68

Collection of cord blood units, 82–83, 100, 151–156, 179

centers for, 297

costs, 233–234

processes used, 80–81, 179

sites for, 100

Colony-forming units (CFUs), 84

granulocyte-macrophage (CFU-GM), 83

megakaryocyte (CFU-M), 33

mixed (CFU-MIX), 78–79

Commissioned papers, 146, 208–271

Committed progenitor cells, 33

Committee on Establishing a National Cord Blood Stem Cell Bank Program, 6, 30, 79, 90

meetings, 146–147

site visits conducted by, 145

Confidentiality, of donors, protecting, 116

Confirmatory typing (CT), 197, 263

Congenital adrenal hyperplasia (CAH), 190



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement